Start-Up Exhibitor

VaxNewMo is an early stage biotechnological company developing next-generation conjugate vaccines against existing and emerging bacterial threats using our proprietary bioconjugation technology. Our platform technology supports the production of polysaccharide-protein conjugates in a simple, one-step enzymatic reaction all within the periplasm of glycoengineered strains of E. coli. Currently, VaxNewMo is developing bioconjugate vaccines for Streptococcus pneumoniae (Pneumococcus), Klebsiella pneumoniae, and Group B Streptococcus.